![]() He provides leadership on the translational aspects of these studies as well as commercial studies such as PISARRO and PRO-105. #Driver evaluation program ecmc trial#He sits on the trial management group of a number of UK ovarian cancer trials including ICON9, CENTURION and PEACOCC. He was UK lead for the SOLO1 trial which led to the first line licence for olaparib in BRCA mutant ovarian cancer and for the recently reported GOG281/LOGS trial of trametinib which is the first ever positive randomised controlled trial in low grade serous ovarian cancer. Professor Gourley is active in ovarian cancer clinical trials. He previously sat on the Scientific Evaluation Committee, Institut National du Cancer in France, the Cancer Research UK Experimental Medicine Expert Review Panel as well as the Commission on Human Medicines Oncology and Haematology Expert Advisory Group. He is the current chair of the Gynaecological Cancer Intergroup (GCIG) Translational Committee and is a member of the Scottish Medicines Consortium and the German Cancer Aid Scientific Review Committee. In 2022, following successful joint bid by CRUK Edinburgh Centre and CRUK Glasgow Centre, he became a Translational Lead of the newly formed Cancer Research UK Scotland Centre. He became Director of the Nicola Murray Centre for Ovarian Cancer in 2016 and Clinical Director of the Cancer Research UK Edinburgh Centre in 2019. He received a Scottish Senior Clinical Fellowship Award in 2010. Charlie was appointed Senior Lecturer in Medical Oncology at the University of Edinburgh in 2005, Reader in Medical Oncology in 2011 and Professor of Medical Oncology (Personal Chair) in 2012. From 1998 to 2005 he trained in Medical Oncology at the Edinburgh Cancer Centre, during which time he was awarded a PhD in ovarian cancer genetics (Edinburgh University) and an NHS Education for Scotland Clinician Scientist Award (2004). ![]() Professor Charlie Gourley graduated in Genetics and Medicine from Glasgow University in 19 respectively. His research spans cytotoxic, small molecule, metabolic and even psychological therapies, but his main focus is immunotherapies, where he is the clinical lead for the Edinburgh Cancer Immunology network and co-lead for the ECMC Immunotherapy Strategy Group. He also continues to work in drug development, as a medical advisor in CRUK’s Centre for Drug Development. In the clinic, he runs the Edinburgh Phase I Cancer Trials Unit and also has a specialty focus on renal cancer. After clinical training in the UK (Cambridge, Edinburgh), Australia (Melbourne) & New Zealand (Christchurch), and research in academia, clinic & industry (AstraZeneca, various UK biotechs), he is now the joint lead for the Edinburgh Experimental Cancer Medicine Centre, where he provides the link between Edinburgh’s laboratory discoveries and their clinical development. Dr Stefan Symeonides is a Medical Oncologist and Senior Clinical Lecturer in Experimental Cancer Medicine at the Cancer Research UK Edinburgh Centre (University of Edinburgh) and at the linked Edinburgh Cancer Centre (NHS Lothian). ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |